埃索美拉唑联合莫沙必利、铝碳酸镁治疗难治性胃食管反流病的临床观察  

Clinical observation of esomeprazole combined with mosapride and hydrotalcite in treatment of refractory gastroesophageal reflux disease

作　　者：陈龙[1] 陈福敏[1] 杜宗汉[1] 周晓晴[1] 

机构地区：[1]南充市中心医院消化内科(川北医学院第二临床医学院),四川南充637000

出　　处：《胃肠病学和肝病学杂志》2013年第1期57-59,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的观察埃索美拉唑、铝碳酸镁、莫沙必利治疗难治性胃食管反流病(rGERD)的临床疗效。方法 120例rGERD患者随机分为3组:A组(n=40)、B组(n=40)和C组(n=40)。分别采用埃索美拉唑+莫沙必利+铝碳酸镁、埃索美拉唑+莫沙必利及铝碳酸镁+莫沙必利治疗,4周及8周评价临床症状及有效率。结果治疗8周后A组在症状评分和内镜分级均较B、C组显著改善(P<0.05)。A组4周、8周后临床症状评分有效率分别为80.0%和92.5%,3组比较差异显著(P<0.05)。结论埃索美拉唑联合莫沙必利、铝碳酸镁是治疗rGERD的有效方法。To observe the clinical efficacy of esomeprazole combined with hydrotalcid and mosapride on refractory gastroesophageal reflux disease. Methods 120 cases of rGERD patients were randomly divided into groups A （ n = 40）, B （ n = 40） and C （ n = 40）, treated with esomeprazole plus hydrotalcite plus mosapride, esomeprazole plus mosapride, and hydrotacite plus mosapride, respectively. The clinical symptoms and effective rate were evaluated after 4 and 8 weeks. Results After 8 weeks of treatment, group A was more significant improvement than group B and C, a significant improvement in the symptom score and endoscopic grade （P 〈 0.05 ）. Efficient of clinical symptom scores after 4 weeks, 8 weeks were 80.0% and 92.5% in group A. Group A is more significant difference than group B, group C （P 〈 0.05）. Conclusion It is an effective method of treatment rGERD with esomeprazole, mosapride, and hydrotalcite.

关 键 词：难治性胃食管反流病 埃索美拉唑 莫沙必利 铝碳酸镁 

分 类 号：R571[医药卫生—消化系统]